Newsroom | 5268 results

BURNABY, Colombie-Britannique--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ : DXCM), leader mondial dans le domaine des biocapteurs de glucose, a annoncé aujourd’hui que Santé Canada a autorisé la mise en marché du système de surveillance continue du glucose (SCG) Dexcom G7 15 jours pour les personnes âgées de 18 ans et plus vivant avec le diabète. Le Dexcom G7 15 jours est le système de SCG homologué par Santé Canada offrant la plus longue durée de port et la meilleure exactitude1-4. Il fournit des v...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will...

RICHMOND HILL, N.Y.--(BUSINESS WIRE)--iHealthScreen, Inc., a healthcare AI company developing Software as a Medical Device (SaMD) for retinal and cardiovascular disease screening and preventive healthcare, today announced FDA 510(k) clearance (K253704) for iPredict-DR™, its AI-powered software that automatically detects more than mild diabetic retinopathy (mtmDR) in adults with diabetes not previously diagnosed with the condition. Diabetic retinopathy is a leading cause of preventable blindness...

MIAMI & BOSTON--(BUSINESS WIRE)--OpenEvidence and the Anticoagulation Forum (AC Forum) today announced a strategic partnership to provide antithrombotic guidance and tools that support decision-making in clinical practice. By combining the AC Forum’s leadership in education and multidisciplinary clinical guidance with OpenEvidence’s advanced artificial intelligence platform, clinicians will gain access to timely and practical evidence in antithrombotic therapy. “Clinicians are increasingly turn...

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc, a leader in AI-powered health technology focused on complex conditions, today announced that it is officially live as an approved Participant in the Centers for Medicare & Medicaid Services (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model. As a credentialed Medicare Part B supplier, Welldoc joins the first cohort of digital health solutions going live with the CMS July 5 launch. Eligible beneficiaries navigating traditio...

NORTH BETHESDA, Md.--(BUSINESS WIRE)--The Foundation for the National Institutes of Health awards the 2026 Montrone-Seigel Prize in Biomedical Sciences to Shingo Kajimura, PhD....

BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED, Inc. (www.TIXiMED.com), a clinical-stage pharmaceutical company developing a novel disease-modifying oral therapy for type 1 diabetes (T1D), today announced the initiation of the Phase 1b Multiple Ascending Dose (MAD) study of TIX100 (NCT07675590), an investigational oral inhibitor of thioredoxin-interacting protein (TXNIP). The TIX100 MAD study is a double-blind, randomized, placebo-controlled trial evaluating the safety, tolerability, and pharmacoki...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Accelerates Global Growth with Launch of Omnipod 5 and Omnipod Discover in Spain, Expanding Access to Tubeless Diabetes Technology...

BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the commercial availability of its Butterfly iQ+ and iQ3 handheld ultrasound devices and mobile application in Brazil through a network of authorized distribution partners. Brazil is the largest medical device market in Latin America and one of the fastest-growing ultrasound markets globally,1,...